Position statement on the hormonal management of adult transgender and gender diverse individuals

@article{Cheung2019PositionSO,
  title={Position statement on the hormonal management of adult transgender and gender diverse individuals},
  author={Ada S. Cheung and Katie Wynne and Jacobus Petrus Erasmus and Sally Murray and Jeffrey D. Zajac},
  journal={Medical Journal of Australia},
  year={2019},
  volume={211}
}
Rising demand for gender‐affirming hormone therapy mandates a need for more formalised care of transgender and gender diverse (TGD) individuals in Australia. Estimates suggest that 0.1–2.0% of the population are TGD, yet medical education in transgender health is lacking. We aim to provide general practitioners, physicians and other medical professionals with specific Australian recommendations for the hormonal and related management of adult TGD individuals. 
Australian endocrinologists need more training in transgender health: A national survey
TLDR
The level of training and confidence of Australian endocrinologists and trainees in the endocrine management of trans and gender diverse individuals in a representative sample was assessed. Expand
Hormone therapy for trans and gender diverse patients in the general practice setting.
TLDR
The aim of this article is to provide GPs working in Australia with a practical guide to prescribe gender-affirming hormone therapy to TGDNB patients. Expand
Feminizing Hormone Therapy Prescription Patterns and Cardiovascular Risk Factors in Aging Transgender Individuals in Australia
TLDR
A greater proportion of trans individuals ≥45 years of age were treated with transdermal estradiol, and the median dose was lower, which is important given the high prevalence of cardiometabolic risk factors in this age group, however cardiovascular risk management guidelines in this demographic are lacking. Expand
Perioperative considerations for transgender women undergoing routine surgery: a narrative review.
TLDR
An overview of the factors influencing the safe care of the transgender woman presenting for routine surgery is provided, including the potential social and pharmacological factors to consider, and anatomical changes to be aware of from previous gender confirming or feminisation surgeries that can influence clinical decision-making. Expand
Approach to Interpreting Common Laboratory Pathology Tests in Transgender Individuals
TLDR
It is proposed that once individuals have commenced gender-affirming hormone therapy, the reference range of the affirmed gender be reported except for PSA or cardiac troponin, which are dependent on organ size. Expand
Estradiol Therapy in the Perioperative Period: Implications for Transgender People Undergoing Feminizing Hormone Therapy
TLDR
There is a need for high-quality prospective trials evaluating the perioperative risk of estradiol therapy in trans people undergoing feminizing hormone therapy to formulate evidence-based recommendations. Expand
The Informed Consent Model of Care for Accessing Gender-Affirming Hormone Therapy Is Associated With High Patient Satisfaction.
TLDR
Initiation of GAHT can be performed in primary care by GPs using an informed consent model and is associated with high patient satisfaction and may be a practical solution to reduce waiting lists in gender clinics. Expand
Testosterone, identity and the body: Exploring cultural definitions of disorder.
Medically-sanctioned testosterone administration has seen increasingly widespread application in the treatment of gender dysphoria (GD). Yet, by comparison, this approach is not medically acceptedExpand
A systematic review of antiandrogens and feminization in transgender women
TLDR
It is unclear whether spironolactone's antagonism of the androgen receptor results in clinically meaningful differences in feminization, and further research with clinically meaningful endpoints is needed to optimize the use of antiandrogens in transgender women. Expand
The Health and Well-Being of Transgender Australians: A National Community Survey
TLDR
Barriers, including widespread discrimination and unemployment, contribute to health inequity and prevalent mental health conditions, and better training for health professionals in the provision of safe, gender-affirming and general health care for trans people is urgently required. Expand
...
1
2
...

References

SHOWING 1-10 OF 52 REFERENCES
Gender‐affirming hormone therapy and the risk of sex hormone‐dependent tumours in transgender individuals—A systematic review
TLDR
Whether tumour risk in transgender individuals differs from the general population, to guide clinical screening recommendations, is sought. Expand
Cross‐sex hormone therapy in Australia: the prescription patterns of clinicians experienced in adult transgender healthcare
Despite increasing demand for transgender healthcare, guidelines for cross‐sex hormone therapy are based on low‐level evidence only. As most data are based on international expert opinions,Expand
Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents
TLDR
Recommendations are made based on available empirical evidence and clinician consensus, and have been developed in consultation with Australian professionals working with the TGD population, TGD support organisations, as well as TGD children and adolescents and their families. Expand
Thrombotic issues in transgender medicine: A review
TLDR
This review highlights the current interventions available in transgender medicine and related potential hematologic complications, and it suggests simple, evidence‐based management going forward. Expand
Size and Distribution of Transgender and Gender Nonconforming Populations: A Narrative Review.
TLDR
The transgender and gender nonconforming population is undergoing rapid changes in size and demographic characteristics and more accurate and precise estimates will be available when population censuses collect data on sex assigned at birth and gender identity. Expand
Understanding and Addressing Hair Disorders in Transgender Individuals
TLDR
A framework for understanding hair disorders in transgender individuals and effective treatment options is provided to provide a thorough understanding of the hormonal treatments that may be used in transgender patients as well the unique and complex biologic characteristics of the hair follicle. Expand
Sex Steroids and Cardiovascular Outcomes in Transgender Individuals: A Systematic Review and Meta‐Analysis
TLDR
Low‐quality evidence suggests that sex steroid therapy may increase LDL‐C and TG levels and decrease HDL‐C level in FTM individuals, whereas oral estrogens may increase TG levels in MTF individuals. Expand
Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7
ABSTRACT The Standards of Care (SOC) for the Health of Transsexual, Transgender, and Gender Nonconforming People is a publication of the World Professional Association for Transgender Health (WPATH).Expand
Mortality and morbidity in transsexual subjects treated with cross‐sex hormones
TLDR
Investigation of mortality and morbidity figures in a large group of transsexual subjects receiving cross‐sex hormone treatment finds that the optimum steroid hormone treatment regimes for transsexual subjects has not yet been established. Expand
Increasing rates of people identifying as transgender presenting to Endocrine Services in the Wellington region.
TLDR
Changes in the number of transgender people seen in the Wellington Endocrine Service are comparable to changes reported overseas, requiring an increased focus on clinical coordination between the relevant medical services and their links to the primary services sector. Expand
...
1
2
3
4
5
...